Drug intelligence / Profile preview

alendronate + cholecalciferol

Development stage
Approved
Lead developer
Merck
Modality
Small Molecules
Administration
Oral
01

Overview

**Alendronate + cholecalciferol** is a once-weekly fixed-dose oral combination of alendronate, a nitrogen-containing bisphosphonate, and cholecalciferol, also known as vitamin D3. Alendronate inhibits osteoclast-mediated bone resorption, while cholecalciferol is converted to active vitamin D metabolites that support intestinal calcium absorption and bone mineral homeostasis. Marketed formulations contain 70 mg alendronate with either 2,800 IU or 5,600 IU cholecalciferol. It is approved for osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis; it is not intended to treat vitamin D deficiency by itself. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1))

Brand names
AdrovanceFosamax PlusFosamax Plus DFosavanceGubangjia
Other names
alendronic acid + colecalciferolalendronate sodium + cholecalciferolalendronate sodium + vitamin D3alendronate + vitamin Dalendronate + vitamin D3
02

Targets

FDPS (Farnesyl pyrophosphate synthase)VDR (Vitamin D receptor)

Beyond the preview

Go deeper on alendronate + cholecalciferol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on alendronate + cholecalciferol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call